Tenax Therapeutics (TENX) Equity Average (2016 - 2017)
Historic Equity Average for Tenax Therapeutics (TENX) over the last 5 years, with Q3 2017 value amounting to $10.7 million.
- Tenax Therapeutics' Equity Average fell 7803.99% to $10.7 million in Q3 2017 from the same period last year, while for Sep 2017 it was $10.7 million, marking a year-over-year decrease of 7803.99%. This contributed to the annual value of $43.8 million for FY2016, which is N/A changed from last year.
- According to the latest figures from Q3 2017, Tenax Therapeutics' Equity Average is $10.7 million, which was down 7803.99% from $12.7 million recorded in Q2 2017.
- In the past 5 years, Tenax Therapeutics' Equity Average ranged from a high of $48.8 million in Q3 2016 and a low of -$1.7 million during Q2 2013
- Over the past 3 years, Tenax Therapeutics' median Equity Average value was $12.7 million (recorded in 2017), while the average stood at $16.7 million.
- Examining YoY changes over the last 5 years, Tenax Therapeutics' Equity Average showed a top increase of 6392.16% in 2013 and a maximum decrease of 17750.15% in 2013.
- Over the past 3 years, Tenax Therapeutics' Equity Average (Quarter) stood at -$1.7 million in 2013, then skyrocketed by 1989.35% to $31.9 million in 2016, then tumbled by 66.43% to $10.7 million in 2017.
- Its Equity Average was $10.7 million in Q3 2017, compared to $12.7 million in Q2 2017 and $15.6 million in Q1 2017.